Incannex reports positive Phase 2 data for IHL-42X in obstructive sleep apnoea; AHI reductions up to 83%

Incannex Healthcare Inc.

• Low- and high-dose IHL-42X achieved statistically significant reduction in AHI vs placebo (p<0.05); max AHI reduction 83% in high-dose group.
• 41.2% of high-dose group achieved >30% AHI reduction; 14.7% had >50% reduction; no reduction in REM sleep.
• 89.5% of patients reporting improvement described change as meaningful; benefits included improved sleep quality and reduced daytime fatigue.
• No serious adverse events; treatment-emergent adverse effects infrequent, mild/moderate; drug well tolerated.
• CEO notes share price volatility, states company is well-capitalized and considering strategic levers including anti-dilution measures.